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Abstract
 
Naturally occurring CD4
 
 
 
CD25
 
 
 
 regulatory T cells appear important to prevent activation of
autoreactive T cells. This article demonstrates that the magnitude of a CD8
 
 
 
 T cell–mediated
immune response to an acute viral infection is also subject to control by CD4
 
 
 
CD25
 
 
 
 T regu-
latory cells (T
 
reg
 
). Accordingly, if natural T
 
reg
 
 were depleted with specific anti-CD25 antibody
before infection with HSV, the resultant CD8
 
 
 
 T cell response to the immunodominant peptide
SSIEFARL was significantly enhanced. This was shown by several in vitro measures of CD8
 
 
 
T cell reactivity and by assays that directly determine CD8
 
 
 
 T cell function, such as proliferation
and cytotoxicity in vivo. The enhanced responsiveness in CD25-depleted animals was between
three- and fourfold with the effect evident both in the acute and memory phases of the immune
response. Surprisingly, HSV infection resulted in enhanced T
 
reg
 
 function with such cells able to
suppress CD8
 
 
 
 T cell responses to both viral and unrelated antigens. Our results are discussed
both in term of how viral infection might temporarily diminish immunity to other infectious
agents and their application to vaccines. Thus, controlling suppressor effects at the time of
vaccination could result in more effective immunity.
Key words: regulatory T cells • vaccine • memory • HSV infection • immunopathology
 
Introduction
 
The generation of T cell immunity is subject to control by
multiple cellular and molecular events. Most is known
about circumstances that positively influence immunity
such as the role of interacting cells, costimulatory mole-
cules, and cytokines. In fact, until recently, the idea that
suppressor cells additionally affect the outcome of im-
mune responses was viewed skeptically. This scenario was
changed by the observations of several groups that T cells
of a defined phenotype (CD4
 
 
 
CD25
 
 
 
) may down-regulate
the severity of lesions caused by autoimmunity and some
other immunopathologies (1–3). To date, the focus of reg-
ulatory T cell (T
 
reg
 
) research has been on their role in tissue
damage events mediated by self-reactive T cells (1, 4). Little
is known about the influence of CD4
 
 
 
CD25
 
 
 
 T
 
reg
 
 cells on
responses to exogenous antigens, especially those expressed
by pathogens. Recently, however, it appears that immuno-
pathological and protective immune responses to intracellular
parasites are also affected by regulatory T cells (5–7). Cur-
rently, the influence of CD4
 
 
 
CD25
 
 
 
 T
 
reg
 
 cells in response
to viruses is largely unknown. This report examines the
role of CD4
 
 
 
CD25
 
 
 
 T
 
reg
 
 cells in primary immune response
to HSV-1 infection in mice. The model chosen for study
was the C57BL/6 (B6) mouse wherein the vast majority of
CD8
 
 
 
 T cells react to a known peptide (SSIEFARL), with
responses to this peptide alone sufficient for protective
immunity in B6 mice (8, 9). Our results show that depletion
of CD25
 
 
 
 T
 
reg
 
 cells before infection results in an elevated
SSIEFARL-specific CD8
 
 
 
 T cell immune response. Further-
more, the responding CD8
 
 
 
 T cells remain activated for a
longer period of time, and the memory responses of regulatory
T cell–depleted animals was elevated around threefold
compared with controls. The adoptive transfer experiments
further demonstrated that the suppressive activity was concen-
trated in CD4
 
 
 
CD25
 
 
 
 T
 
reg
 
 cells. Interestingly, HSV infection
also served to induce the immunosuppressive function of
CD4
 
 
 
CD25
 
 
 
 T
 
reg
 
 cells. Our results are discussed in terms
of their implication to vaccine design and susceptibility to
intercurrent infections in those infected by HSV.
 
Materials and Methods
 
Mice and Virus.
 
Female 5–6-wk-old Thy1.2
 
 
 
 C57BL/6 (B6)
 
and congenic Thy1.1
 
 
 
 B6.PL (H-2
 
b
 
) mice were purchased from
Harlan Sprague-Dawley and Jackson Laboratory and housed in the
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animal facilities at the University of Tennessee. OT-1 mice used
were bred and maintained in the Microbiology Department’s ani-
mal facility. All investigations follow guidelines of the Committee
on the Care of Laboratory Animals Resources, Commission on
Life Science, National Research Council. HSV-1 strain KOS and
KOS (dlsptk) was grown in vero cells obtained from American
Type Culture Collection. The viruses were concentrated, titrated,
and stored in aliquots at 
 
 
 
80
 
 
 
C until use. Titers were measured in
vero cells and expressed as PFU per milliliter.
 
Antibodies and Reagents.
 
PC61 (anti-CD25) hybridoma was
purchased from American Type Culture Collection, and anti-
body was grown in tissue culture roller bottles. For all injections,
an ammonium sulfate cut of PC61 mAb was used. Abs purchased
from BD PharMingen were PerCp anti-CD8
 
 
 
, PE–anti-CD25
(PC61); CD62 ligand (CD62L), CD44, CCR5, CD69, CTL-
associated antigen (CTLA)-4, IFN-
 
 
 
, anti-TCR V
 
 
 
10, Strepta-
vidin-PE, and FITC-labeled V
 
 
 
10, anti-CD25 (7D4), and anti-
CD8
 
 
 
. Carboxyfluorescein diacetate succinimidyl ester (CFSE)
was obtained from Molecular Probes. BrdU staining kit was pur-
chased from BD Pharmingen. HSV gB
 
498–505
 
 peptide (SSIE-
FARL) and chicken ovalbumin (aa 257–264) peptide SIINFEKL
were synthesized and supplied by Research Genetics.
 
Quantitation of HSV-1 in Foot Pad Tissues.
 
The quantitation
of HSV-1 in foot pad (FP) tissue was determined as reported by
Jennings et al. (10). Briefly, the mice were killed at the indicated
time postinfection (p.i.), the FP surface was cleaned with 70%
isopropyl alcohol, and the tissues were removed with a scalpel.
The tissues were stored in virus diluent (PBS supplemented with
0.6 mM CaCl
 
2
 
, 0.5 mM MgCl
 
2
 
/H
 
2
 
O, 20 mg Phenol red, and 50
 
 
 
g gentamicin sulfate per ml) at 
 
 
 
80
 
 
 
C. Tissues were disrupted
by homogenization in 1 ml ground glass grinders (Wheaton) and
centrifuged, and the supernatant was used to assay viral titration
on vero cells. Finally, plaques were visualized with neutral red.
 
Surface and Bromodeoxyuridine Staining.
 
Surface staining was
performed as described previously (11). For bromodeoxyuridine
(BrdU) staining, the BrdU kit from BD PharMingen was used ac-
cording to the manufacturer’s instructions. Briefly, HSV-1–infected
mice received i.p. injection of BrdU (0.8 mg/ml) 1 d before ter-
mination of mice. Spleen cells were stained first with anti-CD8
and V
 
 
 
10 mAb and subsequently with labeled anti-BrdU mAb.
Samples were analyzed on a FACScan™ cytometer using Cell
Quest software (BD Biosciences).
 
SSIEFARL-specific CD8
 
 
 
 T Cell Proliferation.
 
CD8
 
 
 
 T cell
proliferation was evaluated after in vitro restimulation of spleno-
cytes with MHC class I (H-2
 
b
 
)–restricted SSIEFARL peptide.
Briefly, the splenocytes collected from immunized mice were in
vitro restimulated with irradiated SSIEFARL peptide (5 
 
 
 
g/ml)-
pulsed syngeneic T–depleted splenocytes for 3 d. [
 
3
 
H]Thymidine
(1 
 
 
 
Ci/well) was added to each well 18 h before harvest. Har-
vested cells were measured for radioactivity using a 
 
 
 
 scintillation
counter (Inotech).
 
CTL Activity.
 
CTL activity was assessed by a standard 4-h
 
51
 
Cr release assay against labeled target cells as previously described
(12). Splenic T cells obtained from immunized mice were in vitro
restimulated with SSIEFARL peptide (5 
 
 
 
g/ml)-pulsed syngeneic
irradiated T-depleted splenocytes for 5 d and then used as effector
cells. The effector cells were then mixed at various ratios with
 
51
 
Cr-labeled target cells for 4 h. Target cells included SSIEFARL-
pulsed MHC-matched MC-38 (H-2
 
b
 
), mismatched EMT6 (H-2
 
d
 
).
Spontaneous release of 
 
51
 
Cr was determined by incubating the tar-
get cells with medium alone, and maximum release was deter-
mined by adding Triton X-100 to a final concentration of 5%.
The percentage of specific lysis was calculated as follows: 
 
100 
 
 
 
 [(experimental release 
 
 
 
 spontaneous release)/(maximum
release 
 
 
 
 spontaneous release)].
Each experiment was performed twice using triplicate samples.
 
In Vivo CTL Assay.
 
The in vivo CTL assay was done as re-
ported earlier (13). Splenocytes from naive B6 mice were used as
target cells and equally split into two populations. One was pulsed
with 2.5
 
 
 
g gB
 
498–505
 
 peptide for 45 min at 37
 
 
 
C and then labeled
with a high concentration (2.5 
 
 
 
m) of CFSE. The other popula-
tion was unpulsed and labeled with a low concentration of CFSE
(0.25 
 
 
 
m). Equal number of cells from each population (10
 
7
 
)
were mixed together and adoptively transferred i.v. into naive
and HSV-1–infected CD25-depleted and nondepleted B6 mice.
In some experiments, splenocytes were collected either 1 or 4 h
after adoptive transfer from recipient mice, erythyrocytes were
lysed, and cell suspensions were analyzed by FACS
 
®
 
 vantage sys-
tem. Each population was distinguished by their respective fluo-
rescence intensity. Assuming that the number of peptide-pulsed
cells injected is equivalent to the number of no peptide-pulsed
cells injected, the percentage of killing of target cells in unin-
fected animals was determined as:
[(Percentage of CFSE
 
low
 
 – percentage of CFSE
 
high
 
) 
 
 
 
 100]/
Percentage CFSE
 
low
 
.
The percentage killing of target cells in infected animals was
calculated as:
Ratio 
 
  
 
(Percentage of CFSE
 
low
 
/percentage of CFSE
 
high
 
).
Percentage specific lysis 
 
  
 
[1 
 
 
 
 (ratio uninfected/ratio in-
fected) 
 
 
 
 100].
 
Intracellular Cytokine Staining.
 
To enumerate the number of
IFN-
 
 
 
–producing T cells, intracellular cytokine staining was per-
formed as previously described (11). In brief, 10
 
6
 
 freshly ex-
planted splenocytes were cultured in U bottom 96-well plates.
Cells were left untreated, stimulated with SSIEFARL peptide (1
 
 
 
g/ml), or treated with PMA (10 ng/ml) and ionomycin (500
ng/ml), and incubated for 6 h at 37
 
 
 
C in 5% CO
 
2
 
. Brefeldin A
(10 
 
 
 
g/ml) was added for the duration of the culture period to
facilitate intracellular cytokine accumulation. After this period,
cell surface staining was performed, followed by intracellular cy-
tokine staining using a Cytofix/Cytoperm kit (BD PharMingen)
in accordance with the manufacturer’s recommendations. The Ab
used was anti–IFN-
 
 
 
 (clone XMG1.2). The fixed cells were re-
suspended in PBS and analyzed with Cell Quest.
 
Single Cell ELISPOT Assay for IFN-
 
 
 
–secreting Cells.
 
The en-
zyme-linked immunospot (ELISPOT) assay was used for quanti-
fication of cytokine-producing cells as reported by others (14).
Briefly, ELISPOT plates (Millipore) were previously coated with
IFN-
 
 
 
 anti–mouse Ab. The HSV-primed T cells (responder cells)
were mixed with syngeneic splenocytes (stimulator cells) pulsed
with or without gB
 
498–505
 
 (2.5 
 
 
 
g/ml) along with 10 U/well of
human IL-2. Coincubation of the responder and stimulator cells
was continued for 48 h at 37
 
 
 
C. The ELISPOT plates were
washed three times with PBS and three times with PBS/Tween-
20 (PBST), and then biotinylated IFN-
 
 
 
 Ab was added to the
plates for 1 h at 37
 
 
 
C. The spots were developed using nitro blue
tetrazolium (Sigma-Aldrich) and 5-bromo-4-chloro-3-indolyl-
phosphate (Sigma-Aldrich) as a substrate after incubation with al-
kaline phosphatase-conjugated streptavidin (Jackson Immuno-
Research Laboratory) for 1 h and counted 24 h later under a
stereomicroscope.
 
Adoptive Transfer of HSV-1–primed Memory CD8
 
 
 
 T Cells to
CD25-depleted B6 Mice.
 
B6 mice were infected via i.p. route
with 2 
 
 
 
 10
 
6
 
 PFU of HSV-1 in the presence or absence of
CD4
 
 
 
CD25
 
  T reg cells. CD8  T cells were purified from the
spleen of respective groups 90 d p.i. by MACS column, and 107T
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viable CD8  T cells were adoptively transferred to recipient B6
mice, which were challenged within 2 h in the hind FP with 5  
106 pfu of HSV-1 KOS. 2 d before adoptive transfer, the recipi-
ent mice was depleted of Treg cells by PC61 treatment. FP was re-
moved after regular interval of time p.i. and homogenized for vi-
ral titration as described earlier.
CD4 CD25  T Cell Purification and Adoptive Transfer in Synge-
neic B6 Mice. CD4 CD25  T cells were purified as reported by
others (15). Briefly, CD4 columns (R&D Systems) were used for
the isolation of CD4  T cells. CD4 CD25  T cells were purified
by incubating the enriched CD4  T cells with biotin-conjugated
anti-CD25 (15  g/108 cells) mAb in PBS/2% FCS for 15 min at
4 C. The positive magnetic separation was performed with LS 
columns (Miltenyi Biotec) according to the suggested protocol.
The purity of cells ranged from 85 to 95%. In some experiments,
CD4 CD25  T cells purified from naive B6 animals (Thy1.1)
were adoptively transfer into B6 (Thy1.2) or Rag /  mice 24 h
before virus infection. Immune response was analyzed 7 and 28 d
after virus infection.
Cytokine ELISA. The culture supernatants from the bulk test
cultures without addition of any exogenous cytokines were
screened for the presence of IL-10 and IFN- . ELISA plates were
coated with capture Abs for the respective cytokines and incu-
bated at 4 C overnight. The plates were washed with PBS/
Tween 20 and blocked with 3% BSA for 2 h at room tempera-
ture. After washing, serially diluted samples and standards were
added to the plate and incubated at 4 C overnight. The plates
were washed followed by the addition of cytokine-specific detec-
tion antibodies for 2 h. Finally, peroxidase-conjugated streptavi-
din (Jackson ImmunoResearch Laboratory) was added. The color
was developed by adding the substrate (ABTS) solution (Sigma-
Aldrich), and the concentration was calculated with an automated
ELISA reader (SpectraMAX 340; Molecular Devices).
Statistical Analysis. All analysis for statistically significant dif-
ferences were performed with Student’s paired t test. P   0.01
and P   0.05 were considered significant. Results are expressed
as mean   SD.
Online Supplemental Material. Figs. S1 and S2, available at
http://www.jem.org/cgi/content/full/jem.20030171/DC1, show
in vivo depletion and HSV-1 immunization. C57BL/6 mice were
given 1 mg PC61 mAb I.P. (i.p.) 3 d before HSV-1 infection. Ini-
tial kinetics of depletion was studied in uninfected mice. PC61
treated or nontreated C57BL/6 mice were immunized subcutane-
ously in each hind FP with 105 PFU HSV-1 KOS (dlsptk) in 50  l
of PBS. At regular intervals after infection, lymphocytes from
draining lymph node (DLN) and spleen were isolated for pheno-
typic and functional studies. 
Results
In Vivo Depletion of CD4 CD25  Treg Cells Before HSV-1
Infection Enhances Virus-specific CD8  T Cell Responses.
To study the in vivo role of CD4 CD25  Treg cells in reg-
ulating the HSV-specific CD8  T cell immune responses,
B6 mice were treated once with 1 mg of anti-CD25 mAb
PC61 i.p. The kinetics of depletion was studied from day 3
to 21 in spleen of depleted mice. Almost total depletion
was observed by day 3, but by day 21 CD25  regulatory T
cell levels were  80% normal (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20030171/DC1). No
significant depletion of CD25  Treg cells was observed in
mice treated with Rat Ig control (unpublished data).
3 d postdepletion, mice were FP infected with HSV-1
virus, and animals were killed at regular intervals to mea-
sure SSIEFARL-specific CD8  T cell responses in the
draining popliteal LNs and spleen. As is evident in Fig. 1,
peptide-specific CD8  T cell numbers were elevated in the
CD25-depleted mice compared with controls as measured
by four separate assays. Thus, at day 7 p.i., peptide-specific
proliferation in CD25-depleted animals was elevated more
than threefold and twofold in splenocytes and DLN cells,
respectively (Fig. 1 A). By day 40 in the memory phase,
significant differences were still evident in the splenocyte
proliferation response between depleted and nondepleted
animals (Fig. 1 A).
Approximately 65% of gB498–505-specific CD8  T cells in
B6 mice express a highly conserved V 10  TCR, and
these SSIEFARL-specific V 10 CD8  T cells actively
participate in CTL responses against HSV (16). To seek di-
rect in vivo evidence for the influence of CD4 CD25 
regulatory T cells on antigen-specific proliferative re-
sponses, infected animals in both groups were pulsed with
BrdU at day 6 p.i, and 1 d later lymphoid populations were
analyzed by FACS® for evidence of BrdU incorporation.
V 10  cells were gated on FACS® plot, and the assay re-
vealed an average 2.5-fold increase in SSIEFARL-specific
CD8  T cells in splenocytes of the CD25-depleted group
(Fig. 1 B).
For protection against HSV infection, T cell–derived
IFN-  is considered a crucial event (17). Analysis of the
intracellular IFN-  response of splenic CD8  T cells
stimulated by the immunodominant SSIEFARL peptide
revealed significantly enhanced immune responses in
CD25 -depleted animals (Fig. 1 C). Furthermore, the sple-
nocyte cytokine response of depleted animals, as measured
by ELISPOT at 7 d p.i., was around fourfold that of unde-
pleted animals (Fig. 1 D). Similarly, the LN response of
CD25-depleted animals was approximately threefold that
of nondepleting animals. Notably, even after 40 d p.i.,
when levels of regulators had returned to normal, the IFN- 
ELISPOT response in splenocytes (a measure of CD8  T
cell memory) was still elevated around threefold in de-
pleted animals compared with nondepleted controls (Fig. 1
D). Together, these results demonstrate that the immu-
nodominant CD8  T cell response became elevated in
both the acute and memory phase of HSV-infected animals
if CD4 CD25  Treg cells were depleted before infection.
Removal of CD4 CD25  Regulatory T Cells In Vivo En-
hances HSV-1–specific CD8  T Cell Cytotoxic Immune Re-
sponse. Additional assays were performed to compare the
effector functions of CD8  T cells after HSV infection of
Treg-depleted and control mice. Two approaches were
used. First, peptide-specific CTL responses were compared
in splenocytes at different times p.i. By this assay, CTL re-
sponses of CD25 -depleted animals were around fourfold
and threefold compared with those of controls in the acute
and memory phase, respectively (Fig. 2 A). A second
approach employed to compare control versus CD25-
depleted mice was the in vivo CTL assay (13). This
method measures lysis of specific peptide pulsed target cellsT
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Figure 1. Enhancement of anti-
gen-specific CD8  T cell re-
sponses after in vivo depletion of
CD4 CD25  T reg cells before
HSV-1 infection. (A) The kinetics
of SSIEFARL-specific CD8  T
cell proliferation was measured in
vitro in both depleted and non-
depleted mice by [3H]thymi-
dine incorporation. The results
are expressed as cpm. *P   0.01
compared with nondepleted HSV-
infected B6 mice. (N.D., not
done). The experiment shown is
representative of two similar ex-
periments, and error bars reflect
the mean   SD of four mice per
group. The cpm of nondepleted
and CD25 -depleted noninfected
groups was always  1,000 with
no significant difference observed
between the two groups. (B) In
vivo proliferation of V 10 CD8 
T cells was measured by BrdU in-
corporation assay. Mice infected
with HSV-1 3 d postdepletion
were injected i.p. with 100  l
(1 mg) of BrdU solution in PBS
1 d before sacrifice. Mice were
terminated 7 d p.i. to examine
the in vivo proliferation of
CD8 V 10 T cells. Cells were
gated on V 10  cells, and the
percentage of BrdU CD8 V 10  T cells is represented in the upper right quadrant. The data in B are representative of two identical experiments. (C) Kinetics
of HSV-1–specific immune response shows that SSIEFARL-specific CD8  T cells increased in number in PC61-treated mice are also functional as evident by
intracellular IFN-  staining. The experiment shown is representative of two additional experiments. The values shown in these FACS® plots are the mean of
four mice per group. (D) Increase in IFN- –secreting CD8  T cells in B6 mice devoid of CD4 CD25  T cells were also measured by standard ELISPOT
assay. On different days post HSV infection, LNs and spleen cells were analyzed for the number of IFN- –secreting CD8  T cells in response to SSIEFARL
peptide. The bars represent the mean   SD of three different mice of same group and are representative of two similar experiments. *P   0.01 and **P   0.05
compared with untreated HSV-infected B6 mice. (N.D., not done). Without peptide stimulation, there was no significant difference in CD8/IFN- –producing
cells in nondepleted and CD25-depleted HSV-infected mice, and the maximum number obtained at any time point was always  5,000 per spleen.T
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adoptively transferred into infected animals that have effec-
tor CD8  T cells. The assay was performed at 7 d p.i. The
results shown in Fig. 2 B, indicate that CD25 depletion re-
sulted in a mean 83% lysis of specific targets in the spleen
compared with 25% lysis of targets in nondepleted animals
when measured 1 h postadoptive transfer of peptide-pulsed
targets. In uninfected animals, the lysis of peptide-pulsed
targets was always  5–8%. Since the in vivo CTL assay
does not require in vitro expansion, this approach is con-
sidered to be direct evidence that regulatory T cells func-
tion in vivo to diminish the extent of CD8  T cell re-
sponse to HSV infection.
Removal of CD4 CD25  Regulatory T Cells Influences the
Course of Viral Infection. The clearance of acute cutaneous
HSV-1 infection is dependent on T lymphocyte–mediated
immune function, and IFN-  plays an important role in
this process (18). We monitored whether the enhance-
ment of the SSIEFARL-specific CD8  T cell immune re-
sponse observed in the absence of Treg cells affected the
course of viral infection. Our data imply that the acute cu-
taneous viral load in the FP was comparable in both
CD25-depleted and nondepleted B6 mice until day 5.
However, no viral plaques were observed in the CD25-
depleted group on day 6, whereas a significant viral loadT
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was still present in the control nondepleted group (Fig. 3).
By day 8, no virus was detected in the FP of both groups
(data not depicted).
Depletion of CD25  Regulatory T Cells Enhances the Ex-
pression of Cell Surface Activation Markers on Virus-specific
CD8  T Cells. The results reported above indicate that a
consequence of CD25 depletion is that the CD8  T cell
response to the immunodominant peptide SSIEFARL is
significantly elevated. Additional assays were performed to
define if the population of peptide-specific T cells isolated
from CD25-depleted animals differed in phenotypic ex-
pression of activation markers compared with control un-
depleted animals at a time when effector responses were
declining. As shown in Fig. 4, 14 d p.i. an approximately
twofold increase in percentage of cells expressing CCR5
and CD44 on V 10 CD8  T cells (which account for the
majority of SSIEFARL-specific CD8  T cells, [9]) was
found in the Treg-depleted group. Furthermore,  88% of
V 10 CD8  T cells were CD62L high in nondepleted
group compared with 53% in CD25-depleted mice. Differ-
ences were not evident in CD69 and CD25 expression.
Expression of activation markers were also compared day 7
and 21 p.i.; however, no significant differences were ob-
served on these time points (unpublished data). We inter-
pret these observations to indicate that CD25 regulators
might regulate the contraction phase of an immune re-
sponse, and their absence allowed the recently activated
CD8  T cell population to remain in an effector state for
an extended duration.
Inhibition of Virus-specific CD8  T Cell Responses by
CD4 CD25  Regulatory Cells in an Adoptive Transfer
Model. To further establish the role of regulatory T cells
in suppressing virus-specific CD8  T cell immune re-
sponses, an adoptive transfer system was used. Accordingly,
CD4 CD25  and CD4 CD25  T cells were isolated from
naive Thy1.1 mice and adoptively transferred into Thy1.2
B6 mice 24 h before HSV-1 infection. At 7 and 28 d p.i.,
the SSIEFARL-stimulated CD8  T cell IFN-  production
in splenocytes was measured. As shown in Fig. 5, the trans-
fer of CD4 CD25  (but not CD4 CD25  T cells) signifi-
Figure 2. Increased antigen-specific CD8  T cell cytotoxicity in CD25-depleted B6 mice after HSV-1 infection. (A) Splenocytes collected from WT
and CD25-depleted B6 mice at different time points after HSV infection were expanded in vitro with irradiated SSIEFARL-pulsed syngeneic splenocytes
for 5 d and used as effectors in a 4-h 51Cr release assay. The targets included SSIEFARL-pulsed, MHC-matched MC-38 and unpulsed MC-38. The figure
shows only the data for SSIEFARL peptide-pulsed MC-38 targets in lytic units. One lytic unit (LU) is the number of lymphocytes required to give 30%
lysis. The lysis in control targets was insignificant and below the limit for calculation of lytic units. The experiments were performed using four mice, and
data shown above are mean   SD of four mice from one experiment. *P   0.01 and **P   0.05 compared with untreated HSV-infected B6 mice. (B) To
analyze the difference of in vivo SSIEFARL-specific cytotoxicity in vivo in CD25-depleted and nondepleted B6 mice 7 d post HSV-1 infection, syngeneic
spleen cells were pulsed with gB498–505 peptide and labeled with CFSE (2.5  m). To control for antigen specificity, unpulsed syngeneic spleen cells were
labeled with a lower concentration of CFSE (0.25  m). A 1:1 mixture of each target cell population was injected i.v. into both groups of mice. 1 h p.i.,
spleen cells were prepared from individual mice and acquired on a FACS® Vantage system. The percentage of specific lysis was determined as mentioned in
Materials and Methods. The number shown in each plot is the mean of percent antigen specific lysis observed in four mice per group.T
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cantly impaired the intracellular IFN-  and ELISPOT
CD8  T cell responses to HSV-1 (Fig. 5 A). Reduction
was between three and fourfold for intracellular IFN- 
staining (ICG) (Fig. 5 A) and was  2.5-fold for ELISPOT
(Fig. 5 B). Similarly, the in vivo CTL assay also revealed
that adoptive transfer of CD4 CD25  T cells significantly
suppressed the in vivo cytolytic activity of SSIEFARL-spe-
cific CD8  T cells (Fig. 5 C). Together, these results dem-
onstrate that the CD4 CD25  regulatory T cells signifi-
cantly inhibit the virus-specific CD8  T cell immune
response. Similar results were obtained with the adoptive
transfer of purified CD4 CD25  Treg cells with CD25 de-
pleted total SPC (1:5) in a Rag /  mice where SSIE-
FARL-specific CD8/IFN-  production was measured 7 d
p.i. (Fig. S2, available at http://www.jem.org/cgi/content/
full/jem.20030171/DC1).
Additional experiments were performed to measure if
diminished immune responses resulting from the transfer of
CD25  Treg had any effect on viral replication after infec-
tion of the FPs of recipient mice. As is evident in Fig. 5 D,
measurement of viral clearance in the infected FP of trans-
ferred recipient revealed no significant difference over the
first 5 d. However, the transfer of CD4 CD25  Treg re-
sulted in enhanced susceptibility to infection, with mice
failing to clear the virus by day 7. In contrast, the control
group receiving CD4 CD25  T cells cleared the virus by
day 7, and viral titers were significantly diminished on day
6. These experiments indicate that the transfer of additional
CD25  Treg impairs the viral clearance rate, but this is evi-
dent at a time when clearance is mediated by adaptive im-
mune responses.
HSV Infection Activates CD4 CD25  Regulatory T
Cells. Usually CD4 CD25  Treg cells require in vitro ac-
tivation via their TCR to exert their inhibitory functions
(15). How such cells become activated in vivo remains un-
resolved. The results shown in Fig. 6 indicate that one con-
sequence of HSV-1 infection may be potentiation of Treg
cell function. In these experiments, the inhibitory effect
of CD4 CD25  T cells was measured in vitro against
CD8  T cell responses to peptides. Three populations of
Figure 3. Increased rate of viral clearance from the FP of CD25-depleted
HSV-1–infected mice during the primary immune response. Mice were
infected in the hind FPs with 106 pfu HSV-1, and on days 3 to 6 the hind
feet were removed and homogenized in virus diluent. The resulting super-
natant was used in a vero cell based viral plaque assay to determine the virus
titer. The results are expressed as number of pfu of virus per FP. Each
error bar represents the mean and SD of six individual FPs. *P   0.01
compared with CD25-depleted HSV-infected B6 mice.
Figure 4. Removal of CD4 CD25  T cells before HSV infection enhances the expression of activation markers on virus-specific CD8  T cells.
Expression of activation markers on T cells gated on with double positive CD8 V 10  cells in spleen of CD25-depleted and nondepleted mice were
examined. Splenocytes from both groups were collected on day 14 post HSV infection and stained with anti–mouse CD8  and anti–mouse V 10 mAb
in combination with an antibody against on activation marker (anti-CD44, CD62L, CD69, CD25, CCR5) and the appropriate isotype control using
three color FACS® analysis. Histograms are representative of four individual mice from one such experiment, and values reflect the percentage of cells
expressing the respective marker.T
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Figure 5. Adoptive transfer of CD4 CD25  T cells inhibits HSV-1–specific CD8  T cell responses. Purified CD4 CD25  and CD4 CD25  T cells
(2   106/mouse) were adoptively transferred into WT B6 mice 24 h before HSV infection, and the immune response was measured on days 7 and 28 p.i.
(A) On days 7 and 28 p.i., spleen cells were incubated with gB498–505, and CD8/IFN-  production was measured by intracellular staining. The number
shown in each plot is the mean percentage of IFN- –producing CD8  T cells obtained from four mice per group. (B) The resulting decrease in IFN- –
secreting CD8  T cells in B6 mice after adoptive transfer of CD4 CD25  T cells were also measured by a standard ELISPOT assay. On days 7 and 28
post HSV infection, spleen cells were analyzed for the number of IFN- –secreting CD8  T cells in response to SSIEFARL peptide. The error bars
represent the mean   SD of four different mice in the same group. *P   0.05 compared with HSV-infected B6 mice receiving no adoptive transfer.
Without peptide stimulation, there was no significant difference in CD8/IFN- –producing cells between HSV-infected mice receiving either
CD4 CD25  or CD4 CD25  T cells. The maximum number of cells obtained at both time points was always  4,000 per spleen. (C) gB-specific cyto-T
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CD4 CD25  T cells isolated from different groups of ani-
mals were evaluated. These were prepared from naive ani-
mals, animals infected 10 d previously with HSV-1 and
from mice depleted of CD25  T cells before HSV infec-
tion. As shown in Fig. 6 A, CD4 CD25  T cells from na-
ive animals and from Treg-depleted virus-infected mice
failed to inhibit in vitro proliferative responses of SSIE-
FARL- and SIINFEKL-specific CD8  T cells. In contrast,
a dose-dependent inhibition of both SSIEFARL-specific
and SIINFEKL-specific CD8  T cell proliferation oc-
curred when CD4 CD25  T cells isolated from HSV-
infected nondepleted animals were added to cultures. Re-
sults measuring the suppressive effects of the three series of
CD4 CD25  T cells against peptide-induced IFN- 
production measured by ELISA also revealed that only
the population from the undepleted virus infected mice
showed significant inhibitory effects (Fig. 6 B). The sup-
pressive effect mediated by virus-activated CD25  T cells
appeared not to involve IL-10, since neither significant lev-
els of IL-10 were detected in cocultures (unpublished data),
nor did the addition of anti-IL-10 mAb to cultures abro-
gate the suppressive function of the virus-activated Treg
cells (Fig. 6 B).
The Treg activation resulting from HSV infection was
further analyzed in an adoptive transfer assay in which
CD4 CD25  Treg purified from naive Thy1.1 mice were
adoptively transferred (106/mouse) into congenic Thy1.2
B6 recipients. The purity of CD4 CD25  Treg was 93%.
One group of animals was virus infected and the other
acted as noninfected controls. Analysis of spleen cells iso-
lated from recipient mice on day 7 p.i. revealed a threefold
increase in the donor Thy1.1  cells (2.4%   0.4) com-
pared with the uninfected control group (0.7%   0.1).
Furthermore, virus infected animals also demonstrated a
four- to fivefold increase in Treg cells expressing OX-40
and CTLA-4. Around 20% of adoptively transferred Treg
cells expressed CD69 (Fig. 7). Interestingly, in virus-
infected animals more than half of the donor Treg cells lost
their CD25 marker, and the percentage of CD4 CD25 
T cells was only 40%, whereas in noninfected animals
 95% of Treg cells were still CD25 positive. These results
add further evidence that HSV infection leads to activation
of Treg function.
Memory CD8  T Cells Generated in the Absence of
CD4 CD25  T Cells Confer Greater Protection upon Rechal-
lenge. It has been shown earlier that HSV-specific CTL
provide a level of protection against acute HSV infection
(10). To evaluate the ability of HSV-specific memory
CD8  T cells generated in the presence or absence of
CD4 CD25  T reg cells to mediate protection, CD8  T
cells were purified 90 d p.i. from splenocytes and trans-
ferred to naive recipients that were then infected via the FP
with virus. Animals were killed at intervals to measure viral
clearance from FPs. The experiment revealed that the pro-
tection was better in the recipient of CD8  T cells taken
from CD25-depleted animals on days 4 and 5 when com-
pared with control group (Fig. 8). Furthermore, by day 5,
virus could only be demonstrated in the recipients of
CD8  T cells from untreated animals, and all animals were
negative by day 6. These results suggest that CD25  Treg
cells may indeed exert long term effects on the resulting
memory CD8  T cell pool.
Discussion
This report demonstrates that the magnitude of a T cell–
mediated immune response to an acute viral infection is
subject to control by CD4 CD25  T reg. Accordingly, if
Treg were depleted with specific anti-CD25 antibody be-
fore infection with HSV, the resultant CD8  T cell re-
sponse to the immunodominant peptide SSIEFARL was
significantly enhanced. This was shown by several in vitro
measures of CD8  T cell reactivity and by assays that di-
rectly determine CD8  T cell function, such as prolifera-
tion and in vivo cytotoxicity. The enhanced responsiveness
in CD25  T cell–depleted animals was between three-
and fourfold with the effect evident both in the acute
and memory phases of the immune response. Moreover,
CD8 -specific T cells retained an activation phenotype for
longer periods in depleted animals. Other experiments
demonstrated that HSV infection itself appeared to act as a
means of inducing and/or activating Treg. Our results imply
that procedures that minimize the effects of Treg at the time
of immunization could benefit HSV vaccination proce-
dures. Given the poor track record of past vaccines against
toxicity was also measured by an in vivo CTL assay to analyze differences
in SSIEFARL-specific cytotoxicity after adoptive transfer of CD25  or
CD25  CD4  T cells. On day 7 post HSV-1 infection, syngeneic spleen
cells were pulsed with gB498–505 peptide and labeled with CFSE (2.5  m).
Unpulsed syngeneic spleen cells were labeled with a lower concentration
of CFSE (0.25  m). A 1:1 mixture of each target cell population was in-
jected i.v. into both groups. 4 h p.i., spleen cells were prepared from indi-
vidual mice and acquired on a FACS® vantage system. Specific lysis was
calculated as mentioned in Materials and Methods. The number shown in
each plot is the mean percent antigen specific lysis observed in four mice
per group. *P   0.05 compared with group with CD4 CD25  T cell
adoptive transfer. (D) Adoptive transfer of CD25  T reg delays the viral
clearance in HSV-infected mice. Each bar represents mean and SD of six
individual FPs. *P   0.05 compared with HSV-infected B6 mice receiv-
ing CD4 CD25  T cells.T
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HSV, modulating suppression could be a maneuver worth
considering to improve such vaccines.
Since the concept of regulatory cells was reawakened by
the observations of several groups (1, 15, 19, 20), it has be-
come evident that the intensity of many immune inflam-
matory reactions are subject to control by Treg. The initial
focus was on organ-specific autoimmunity, but immu-
nopathological reactions to foreign exogenous antigens,
including those expressed by microorganisms, are also in-
fluenced by Treg (3, 5, 6, 21). So far, studies on micro-
organisms have focused on nonviral intracellular pathogens
and emphasized immunopathology.
Figure 6. CD4 CD25  T cells isolated from HSV-1–infected nondepleted B6 mice suppress CD8  T cells proliferation to both HSV-specific and
unrelated antigens. (A) HSV-1–primed CD8  T cells or OT-1 CD8  T cells (2   106/ml) were stimulated with either SSIEFARL or SIINFEKL
peptide-pulsed, T-depleted splenocytes (106/ml) in the presence of CD4 CD25  T cells isolated from either naive, nondepleted, or CD25-depleted B6
mice 10 d post HSV-1 infection. The proliferation was measured in vitro by [3H]thymidine incorporation assay, and the results are expressed as cpm. The
basal level of proliferation of CD4 CD25  T cells isolated from each group was always  5,000 with maximum proliferation observed in CD4 CD25 
T cells purified from CD25-depleted virus-infected mice. (B) CD4 CD25  T cells isolated from naive and virus-infected mice were cocultured (106/ml)
with HSV-1–primed CD8  T cells (2   106/ml) stimulated with SSIEFARL-pulsed APCs (2   106/ml), and IFN-  secretion in cultures was measured
by ELISA as mentioned in Materials and Methods. Anti–IL-10 mAb (5  g/ml) was also added in some of the cocultures to determine the effect on IFN- 
production. No spontaneous IFN-  production was observed in CD4 CD25  T cells isolated from either group. *P   0.01 when compared with wells
containing no Treg cells and **P   0.05 when compared with wells containing Treg. Results from one representative experiment are shown.T
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This report analyzes the role of CD4 CD25  Treg in a
virus infection and addresses their effects on resultant im-
munoprotective responses. Both by removing Treg and by
adoptive transfer studies, our results clearly showed that the
CD8  T cell–mediated immune responses to HSV were
significantly limited by the action of naturally occurring
CD25  T cells. This was shown by measures of prolifera-
tion, cytokine production, and cytotoxicity. In the B6
mouse strain used for such studies, the CD8  T cell re-
sponse is overwhelmingly dominated by a reactivity to the
peptide SSIEFARL (9). Moreover, responses to SSIEFARL
alone can account for functional systemic and mucosal im-
munity to HSV in B6 mice (12). Most striking was the ob-
servation, using the recently described in vivo cytotoxicity
assay, a direct measure of T cell function that cytotoxicity
in the absence of Treg in infected, depleted animals was
markedly higher than in nondepleted controls tested under
the same conditions.
Further, support for the influence of CD25  Treg on the
level of immunity to infection came from adoptive transfer
experiments. These results showed that the transfer of
CD25  cells into naive B6 mice and Rag /  recipients re-
sulted in suppressed CD8  T cell responses after virus in-
fection. Finally, mice depleted of CD25  T cells before in-
Figure 7. Activation of CD4 CD25  T cells by HSV infection in an adoptive transfer model. CD4 CD25  T cells purified from Thy1.1 B6 mice
were adoptively transferred into congenic Thy1.2 B6 recipients. One group was infected 14 h posttransfer and the other acted as noninfected controls.
On day 7, spleen cells isolated from both groups were gated on the Thy1.1 population and analyzed for the expression of the activation markers such as
OX-40, CTLA-4, CD69, and CD25 on CD4  T cells.
Figure 8. Adoptive transfer of HSV-specific memory CD8  T cells
generated in the absence of Treg results in enhanced viral clearance than
those generated in the presence of CD25  regulatory T cells. Splenic
MACS purified CD8  T cells isolated from depleted and nondepleted
animals 90 d p.i. were adoptively transferred into CD25-depleted naive B6
mice. 24 h posttransfer, mice were challenged in the hind FPs with 5   106
pfu of HSV-1 KOS. The level of infectious HSV in the FP was observed
from day 2 to 5 postchallenge. *P < 0.05. A higher virus load was always ob-
served in CD25-depleted, HSV-infected group without any adoptive transfer
compared with the groups with adoptive transfer (data not depicted).T
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fection cleared virus from infected FPs more effectively
than did nondepleted controls. Together, the results of
both depletion and adoptive transfer experiments indicate
that the extent of virus-specific immunity is limited by
CD4 CD25  Treg cells.
Currently, it is not clear how regulatory cells are induced
and act to modulate effector cell function, especially of
CD8  T cells. Work in well-studied systems indicates that
CD25  Treg are induced in the thymus and express TCR
that recognize self-peptides (22–25). Activation requires
TCR interaction, but suppression itself is nonspecific and
in some systems appears mediated by TGF- , CTLA-4, or
IL-10 (19, 26–28). A possible mechanism by which the im-
mune response to pathogens might be modulated by Treg
might involve either direct or indirect reactivity with
pathogen specific antigens. This could be achieved, for ex-
ample, by the pathogen possessing superantigen activity.
Such a scenario was suggested for mouse mammary tumor
virus (29), which expresses a superantigen. However, no
known superantigen activity is encoded by HSV. More-
over, it is unlikely that under normal infection conditions
HSV would interact directly with more than a minute frac-
tion of the population of CD25  regulatory T cells. Hence,
the means by which HSV induces Treg activation is more
likely to represent a paracrine event mediated by cytokines
(such as IL-12/IL-18), stress proteins, or other activation
molecules.
Curiously, our results did unearth evidence that HSV in-
fection resulted in the activation and potentiation of Treg
cell function. Accordingly, CD25  T cells taken from in-
fected animals after the peak of effector activity had en-
hanced regulatory activity against CD8  T cell proliferative
responses in vitro. This regulatory effect was not confined
to HSV antigens, since the inhibition, which did not re-
quire additional in vitro viral Ag stimulation, was demon-
strated against CD8  T cell proliferative responses to the
unrelated OVA408–419 peptide. Further, we believe that
CD4 CD25  T cells purified from CD25-depleted HSV-
infected animals were enriched in effector CD4  T cells
and did not have immunosuppressive activity. Currently,
we lack a mechanistic explanation for the induction or ex-
pression of the regulation, but the effect appeared not to
involve IL-10. In our system, use of anti–IL-10 mAb under
in vitro conditions failed to inhibit the CD25  Treg-medi-
ated immunosuppressive activity. However, we cannot rule
out the possibility that CTLA-4 or TGF-  (membrane
bound or secreted) mediated the suppression. Conceivably,
the induction of regulatory cells may be a common event
with several virus infections and may account for the tran-
sient immunosuppression that often occurs during or after
infection (30–33). The process and its implication for resis-
tance to secondary infection require further study.
Our results indicate that a regulatory response by
CD4 CD25  T cells serves to limit the immunodominant
CD8  T cell response to infection by HSV. The effect was
evident and approximately equal in magnitude in both the
acute and memory phases. Such observations may support
the hypothesis that the generation of the memory pool is
regulated by the effector response (34, 35). However, some
differences in average phenotype of specific CD8  T cells
were observed between Treg-depleted and nondepleted an-
imal in the acute population. Accordingly, in CD25 -
depleted animals, effector CD8  T cells appeared to remain
activated for a longer duration. Our results indicate that the
Treg function, activated as a consequence of HSV infection,
may contribute to the contraction phase of the immune re-
sponse. In turn, the absence of Tregs may allow activated ef-
fector cells to exist for an extended period. Studies also re-
vealed that the increased pool of memory CD8  T cells
generated in CD25 -depleted animals had enhanced cyto-
toxicity and conferred increased protection against viral
challenge with HSV-1 in comparison to memory CD8  T
cells generated in the presence of Treg cells.
Finally, our results may have an impact on vaccine de-
sign, especially against agents such as HSV, for which satis-
factory vaccines are still unavailable. These studies infer that
immunity can be elevated if existing Treg responses are in-
hibited before immunization/infection. Clearly, it would
not be practical to limit the function of Treg with antibody,
the approach used in our experiments, but other more
practical procedures might be developed to limit Treg func-
tion during vaccination. Furthermore, it could be that
postvaccinal Treg suppression would be an effective proce-
dure to enhance immunity as was most recently implied by
the studies of Mittrucker et al. (36). It would also seem that
vaccines should be evaluated in terms of their susceptibility
to inhibitory Treg responses and whether this affects the po-
tency of the resulting T cell functional immunity. We are
currently evaluating such ideas in our laboratory.
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